ArticleExpert review of anti-infective therapy2013
A novel mechanism of immune evasion mediated by Ebola virus soluble glycoprotein.
Article in Expert review of anti-infective therapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 16 citations in OpenAlex.
- Reverse genetics of parrot bornavirus 4 reveals a unique splicing of the glycoprotein gene that affects viral propagation.Journal of virology · 2023Article
- Development of an antigen detection assay for early point-of-care diagnosis of Zaire ebolavirus.PLoS neglected tropical diseases · 2020Article
- Overexpression of Ebola virus envelope GP1 protein.Protein expression and purification · 2017Article
- The Ebola virus VP35 protein binds viral immunostimulatory and host RNAs identified through deep sequencing.PloS one · 2017Article
- Pre-symptomatic diagnosis and treatment of filovirus diseases.Frontiers in microbiology · 2015Review
- In silico analysis suggests interaction between Ebola virus and the extracellular matrix.Frontiers in microbiology · 2015Article
- Structures of protective antibodies reveal sites of vulnerability on Ebola virus.Proceedings of the National Academy of Sciences of the United States of America · 2014Article
- Protein engineering strategies for the development of viral vaccines and immunotherapeutics.FEBS letters · 2014Review
- Human Ebola virus infection in West Africa: a review of available therapeutic agents that target different steps of the life cycle of Ebola virus.Infectious diseases of poverty · 2014Article
- Reflections on the Ebola Public Health Emergency of International Concern, Part 1: Post-Ebola Syndrome: The Silent Outbreak.Journal of global infectious diseasesArticle
Corrections and comments
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Ebola viruses encode two glycoproteins (GPs): a membrane-associated GP that is present in the viral membrane and mediates viral attachment and entry into host cells; and a secreted, nonstructural glycoprotein (sGP) that is identical to GP over approximately 90% of its length. A recent study by Mohan and colleagues attributes a novel immune evasion mechanism dubbed 'antigenic subversion' to sGP. Using DNA immunization in mice, the authors demonstrate that sGP elicits antibodies that crossreact with GP, but these antibodies are non-neutralizing. Coimmunization with sGP plus GP or sequential immunizations with GP and sGP direct the host antibody response toward non-neutralizing epitopes. Therefore, the production of sGP may prevent effective neutralization of the virus during Ebola virus infection, and may reduce the effectiveness of vaccines that rely upon neutralizing antibody responses.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.